Biochemical markers in osteoporosis: Usefulness in clinical practice;Marcadores bioquímicos en osteoporosis. Utilidad en la práctica clínica

Reumatologia Clinica

Volumn 8, Issue 3, 2012, Pages 149-152

  Romero Barco, Carmen M ^a   Manrique Arija, Sara ^a   Rodríguez Pérez, Manuel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Biochemical markers; Biological variability; Fracture; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER;

ARTICLE; BONE REMODELING; BONE TURNOVER; CLINICAL EVALUATION; CLINICAL PRACTICE; FRACTURE; HUMAN; OSTEOPOROSIS; RISK FACTOR;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DECISION SUPPORT TECHNIQUES; HUMANS; OSTEOPOROSIS;

EID: 84860532504     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.05.010     Document Type: Article

References (34)

1. Torres E., Mezquita P., De la Higuera M., Fernández D., Muñoz M. Actualización sobre la determinación de marcadores de remodelado óseo. Endocrinol Nutr 2003, 50:237-243.
2. Ebeling P., Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol 2001, 15:385-400.
3. Szulc P., Delmas P. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008, 19:1683-1704.
4. Camacho P, Kleerekoper M. Biochemical markers of bone turnover. En: Murray J. Favus, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6.a ed. Washington: American Society for Bone and Mineral Research; 2006. p. 127-33.
5. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. Committee of Scientific Advisors of the International. Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000, 11(Suppl 6):2-17.
6. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30:886-890.
7. Brown J.P., Albert C., Nassar B.A., Adachi J.D., Cole D., Davison K.S., et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009, 42:929-942.
8. Booth S.L., Broe K.E., Peterson J.W., Cheng D.M., Dawson-Hughes B., Gundberg C.M., et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab 2004, 89:4904-4909.
9. Calvo M.S., Eyre D., Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996, 17:333-368.
10. Robins S.P., Duncan A., Riggs B.L Direct measurement of free hydroxypiridinium crosslinks of collagen in urine as new markers of bone resorption in osteoporosis. En: Christiansen C Overgaad K editores Osteoporosis Copenhague: Osteopress 1990, 465-468.
11. Miller P., Hochberg M., Wehren L.E., Ross P.D., Wasnich R.D. How useful are measures of BMD and bone turnover?. Curr Med Res Opinion 2005, 21:545-554.
12. De la Piedra C., Díaz M.A. Correlación entre el telopéptido carboxiterminal del colágeno tipo I y la densidad mineral ósea medida por DEXA en la osteoporosis postmenopáusica. REEMO 1992, 1(Suppl B):30.
13. Garnero P. New biochemical markers of bone turnover. IBMS Bonekey 2008, 5:84-102.
14. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000, 15:1337-1345.
15. Srivastava A.K., Mohan S., Singer F.R., Baylink D.J. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 2002, 31:62-69.
16. Navarro L., Blázquez J.A., Del Pino J., Almar R., Cháfer M., Mateos F. Utilidad clínica de los marcadores bioquímicos de remodelado óseo en la mujer posmenopáusica reciente: estudio longitudinal a 2 años. Med Clin (Barc) 2008, 131:333-338.
17. Melton L.J., Khosla S., Atkinson E.J., O'Fallon W.M., Riggs B.L. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997, 12:1083-1091.
18. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmos P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Matab 1994, 79:1693-1700.
19. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641-1647.
20. Singe M.D., Frederick R., Eyre D., David R. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008, 75:739-750.
21. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
22. Eastell R., Krege J.H., Chen P., Glass E.V. Reginster J-Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006, 22:61-66.
23. Riggs B.L., Melton L.J., Oófallon W.M. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18:197-201.
24. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1587-1589.
25. Dobnig H., Sipos A., Jiang Y., Fahrleitner A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
26. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613.
27. Chesnut C.H., Bell M.D., Clark M.D., Drinkwater P.B., English M.D.S.C., Johnston C.C., et al. Hormone replacement therapy in postmenopausal women: urinary n-telopeptide of type i collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997, 102:29-37.
28. Seibel M.J., Naganathan V., Barton I., Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004, 19:323-329.
29. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Molecular Diagnosis & Therapy 2008, 12:157-170.
30. Robbins J.A., Schott A.M., Garnero P., Delmas P.D., Hans D., Meunier P.J. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporosis Int 2005, 16:149-154.
31. Ross P.D., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998, 13:297-302.
32. Vasikaran S.D. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008, 45:221-258.
33. Vesper H.W., Demers L.M., Eastell R., Garnero P., Kleerokoper M., Robins S.P., et al. Assesment nad recommendations on factors contributing to preanalytical variability of urinary pyridinolina and deoxypiridinolina. Clin Chem 2002, 48:220-235.
34. Miller P.D., Baran D.T. Practical clinical application of biochemical markers of bone turnover. J Clin Densitometry 1999, 2:323-342.